LERIGLITAZONE

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H20N2O4S
Molecular Weight	372.438
Optical Activity	( + / - )
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of LERIGLITAZONE

Structure Search

SMILES

CC(O)C1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1

InChI

InChIKey=OXVFDZYQLGRLCD-UHFFFAOYSA-N

InChI=1S/C19H20N2O4S/c1-12(22)14-4-5-15(20-11-14)8-9-25-16-6-2-13(3-7-16)10-17-18(23)21-19(24)26-17/h2-7,11-12,17,22H,8-10H2,1H3,(H,21,23,24)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8978836

Hydroxypioglitazone (M-IV) is an active metabolite of the peroxisome proliferator-activated receptor γ (PPARγ) agonist pioglitazone. Experiments in vitro have shown that hydroxypioglitazone was more efficient than the parent drug in stimulating lipid synthesis.

Approval Year

PubMed

PubMed

Title	Date	PubMed
Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone.	1996 Dec 20	8978836

Name

Type

Language

LERIGLITAZONE

Official Name

English

leriglitazone [INN]

Common Name

English

LERIGLITAZONE [USAN]

Common Name

English

HYDROXYPIOGLITAZONE

Common Name

English

2,4-THIAZOLIDINEDIONE, 5-((4-(2-(5-(1-HYDROXYETHYL)-2-PYRIDINYL)ETHOXY)PHENYL)METHYL)-

Systematic Name

English

MIN-102

Code

English

ALL-AMBO-5-((4-(2-(5-(1-HYDROXYETHYL)PYRIDIN-2-YL)ETHOXY)PHENYL)METHYL)-1,3-THIAZOLE-2,4(3H,5H)-DIONE

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

552716

Created by admin on Fri Dec 15 16:38:10 GMT 2023 , Edited by admin on Fri Dec 15 16:38:10 GMT 2023

FDA ORPHAN DRUG

700919

Created by admin on Fri Dec 15 16:38:10 GMT 2023 , Edited by admin on Fri Dec 15 16:38:10 GMT 2023

Code System Code Type Description

EU-Orphan Drug

EU/3/16/1770(POSITIVE)

Created by admin on Fri Dec 15 16:38:10 GMT 2023 , Edited by admin on Fri Dec 15 16:38:10 GMT 2023

PRIMARY

Treatment of adrenoleukodystrophy 18/11/2016 Positive

CAS

146062-44-4

Created by admin on Fri Dec 15 16:38:10 GMT 2023 , Edited by admin on Fri Dec 15 16:38:10 GMT 2023

PRIMARY

EVMPD

SUB196367

Created by admin on Fri Dec 15 16:38:10 GMT 2023 , Edited by admin on Fri Dec 15 16:38:10 GMT 2023

PRIMARY

PUBCHEM

4147757

Created by admin on Fri Dec 15 16:38:10 GMT 2023 , Edited by admin on Fri Dec 15 16:38:10 GMT 2023

PRIMARY

INN

10868

Created by admin on Fri Dec 15 16:38:10 GMT 2023 , Edited by admin on Fri Dec 15 16:38:10 GMT 2023

PRIMARY

NCI_THESAURUS

C170108

Created by admin on Fri Dec 15 16:38:10 GMT 2023 , Edited by admin on Fri Dec 15 16:38:10 GMT 2023

PRIMARY

EPA CompTox

DTXSID30399914

Created by admin on Fri Dec 15 16:38:10 GMT 2023 , Edited by admin on Fri Dec 15 16:38:10 GMT 2023

PRIMARY

USAN

GH-65

Created by admin on Fri Dec 15 16:38:10 GMT 2023 , Edited by admin on Fri Dec 15 16:38:10 GMT 2023

PRIMARY

SMS_ID

100000182339

Created by admin on Fri Dec 15 16:38:10 GMT 2023 , Edited by admin on Fri Dec 15 16:38:10 GMT 2023

PRIMARY

DRUG BANK

DB15021

Created by admin on Fri Dec 15 16:38:10 GMT 2023 , Edited by admin on Fri Dec 15 16:38:10 GMT 2023

PRIMARY

FDA UNII

K824X25AYA

Created by admin on Fri Dec 15 16:38:10 GMT 2023 , Edited by admin on Fri Dec 15 16:38:10 GMT 2023

PRIMARY

ACTIVE MOIETY


					K824X25AYA

PARENT (METABOLITE ACTIVE)


					X4OV71U42S

SALT/SOLVATE (PARENT)


					WN9K42SAM6

LERIGLITAZONE HYDROCHLORIDE